GLOW trial: A 4-year update on fixed-duration ibrutinib + venetoclax in previously untreated CLL
Here, we summarize the 4-year follow-up data from the phase III GLOW trial investigating fixed duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab in previously untreated chronic lymphocytic leukemia published by Niemann, et al.1 in The Lancet Oncology.